HER-2 expression

Great discussion on HER2-low expression by 🌎 innovators of #breastcancer @BCJoyceO @TexasOncology & Dr. Sara Hurvitz @UCLAHealth 🎯 🧬 #wintheday (@chase_wasson)

Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer @ErikaHamilton9 @PTarantinoMD @BurrisSkip @SarahCannonDocs @DanaFarber #bcsm #OncLiveIPC https://t.co/sPMkOpTjbz (@OncLive)

Expanding Definitions of #HER2 Expression Mediate the Role of #ADCs in #BreastCancer https://t.co/zLa8sXu8ww via @onclive (@Rndubois)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. https://t.co/9ljWfZPHk0 @NatureMedicine @EdiBrogi @rovingatuscap @fcschmitt @TheISBP @LuisBlancoJrMD @PTarantinoMD (@HannahYWen)

Trastuzumab deruxtecan exhibits the highest objective response rate in patients with HER2+ metastatic #BreastCancer, but clinical activity is also observed in patients with HER2- or non-expressing tumors @fermosele @FAndreMD @GustaveRoussy #BCSM https://t.co/xciHmNO1wQ (@NatureMedicine)

Assessing HER2 Expression in Metastatic Colorectal Cancer: @marshalj23, @CathyEngMD, @GIcancerDoc, @aparna1024, and Stacey A. Cohen, MD discuss. https://t.co/7YjpY9yIyM via @onclive (@RueschCenter)

A8: The use of quantitative immunofluorescence is one example of detecting low levels of HER2 expression in breast cancer https://t.co/OJWscCm0uU #HER2low #PathTwitter #BreastPath (@DrShiWei)

A8: Since a subset of patients with TNBC have low levels of HER2 expression, we may see clinicians use the term “HER2-low TNBC” #HER2low #PathTwitter #BreastPath #ASCO23 (@Baskotacytopath)

Q7: What happens to HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer? #asco23 https://t.co/OpQKvhiQcB #HER2low #PathTwitter, #BreastPath @feldmanm30 @Baskotacytopath @DrBuiPathology @drshiwei (@ASCP_Chicago)

I saw this and thought of you and #bcsm colleagues. Is the statement regarding “HER2-Low” considered controversial? "...it is premature to create new result categories of HER2 expression (eg, HER2-Low, HER2-Ultra-Low).…” Inquiring minds want to know. 😆 (@cancerassassin1)

🔊 Improve your understanding of molecular testing recommendations to assist with treatment selection in patients with HER2-expressing #GICancers. 💻 Join Drs. EElimova, Ku, & Pant (@DrShubhamPant) in the live broadcast happening now❗️ #ASCO23 https://t.co/uf82egUcPd #ASCO23 (@PeerView)

TROPiCS-02 trial: SG continues to show benefit vs TPC with additional follow up in HR+/HER2- MBC 35% ⬇️ in risk of progression 21% ⬇️ in risk of death ☑️benefit seen regardless of Trop2 expression and HER2 status(low vs null) @stolaney1 #bcsm #ASCO23 @OncoAlert (@YAbdouMD)

Better understand molecular testing recommendations to assist with treatment selection in patients with HER2-expressing #GICancers by registering for this Live Virtual Symposium on 6/8 at 7 PM EDT with Drs. Elimova, Ku, & Pant (@DrShubhamPant): https://t.co/uf82egUcPd #ASCO23 (@PeerView)

#ASCO23 DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors https://t.co/Cf3siSdH6T (@Latinamd)

HER2 is a relevant target in many tumor types In DESTINY-PanTumor02, T-DXd showed activity across HER2 expressing many solid tumors ORR 37.1% in all patients and 61.3% in patients with IHC 3+ with DOR 11.8 months in all patients and 22.1 months in patients with IHC 3+! #ASCO23 (@chulkimMD)

@stolaney1 presents updated survival data for sacituzumab in HR+/HER2- #MBC: 3.3 mo ⬆️ OS benefit (21% ⬇️ in risk of death) regardless of Trop-2 expression and in both HER2 0 and low populations. #ASCO23 #bcsm (@drteplinsky)

Elegant poster discussion on HER2 0 vs 1+ by @RimmPathology of @YaleSOM **To assess HER2 low, we need to measure - not read - HER2 expression** Probably not many HER2 0 breast cancers when mRNA is measured #ASCO23 #bcsm (@MVanMeterMD)

HER2-Low MBC poster discussion by @RitaNandaMD of @UChicagoMed T-DXd assoc with improved PFS over TPC in all biomarker groups (DB04) HER2 expression changes over time and between sites ADC sequencing - small study suggests changing target can be effective #ASCO23 #bcsm (@MVanMeterMD)

@ASCO Abstract # 575 'Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.' #ASCO23 @LauraSofiaMuno9 @eleonora_nicolo @eleniandreop @JeannineDonahue @MCristofanill @LANewmanMD @CiglerTessa (@CtcLaboratory)

In metastatic breast cancer treated with targeted therapy and endocrine therapy, new research shows no difference in survival between patients with HR positive disease with low HER2 vs. those with no HER2 expression https://t.co/lqEwgZXAf3 @ASCOPost @JAMouabbi #EndCancer (@MDAndersonNews)

Among 100 patients with mostly stage II, ER+/HER2+ early breast cancer, 12 weeks of the chemo-free regimen ET+HP led to a pCR rate of 23%, which raised to 55% among pts with high ERBB2-expressing tumors. We need precision in our treatments for HER2+ eBC. https://t.co/eq2qq1yYg6 (@PTarantinoMD)

Recent cohort study of @JAMouabbi and colleagues suggests low expression of ERBB2 in HR+ advanced #breastcancer would not deteriorate effectiveness of first-line therapy with CDK4/6 inhibitor or second-line alpilisib/everolimus https://t.co/LlMd4qFRXj #VisualAbstract #oncology (@mdwrtcom)

also, stay tuned for this mini-oral from my group! 3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (ID 48) @_SOLTI… https://t.co/rfUtZabNh8 (@prat_aleix)

A6: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 NCT04400695 #HER2low #PathTwitter #BreastPath https://t.co/FB3ccRzKS3 (@KhouryThaer)

A6: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors NCT05461768 #HER2low #PathTwitter #BreastPath https://t.co/QZ761jYtEH (@DrBuiPathology)

Emerging Landscape of Targeted Therapy of Breast Cancers With Low HER2 Protein Expression | Archives of Pathology & Laboratory Medicine. Just published! #HER2 #biomarker #breast #cancer #pathtwitter ⁦@MoffittNews⁩ ⁦ https://t.co/Q0Gn8qTBle (@DrBuiPathology)

Next up at today's Oncology Congress - Harold Burstein, MD, PhD, of @harvardmed & @DanaFarber will present on HER2-expressing metastatic #breastcancer. Watch here and earn free CME/CE: https://t.co/t7cnnWMCQn @DrHBurstein (@ruralhealthcme)

Exactly! Which seems counterintuitive, right? I have some doubts about that HER2 expression classification, and I would love to see the images of HER2 IHC from this trial. Just a reminder: the antibody used to stain HER2 (4B5) is not approved in sarcoma. (@FlaviaMichelini)

T-DXd for HER2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial @JCO_ASCO 32 pts (10 pts HER2 1+) HER2-High and HER2-Low ORR➡️54.5%-70% PFS➡️6.2-6.7 m OS➡️13.3 m-NR >G3 AE➡️61% In the ADC (T-DXd) era, its time to change the definition of… https://t.co/TXrKL5xamz (@dr_yakupergun)

The #STATICE phase 2 trial of T-DXd for HER2-expressing uterine carcinosarcoma is out on JCO. Of 32 patients receiving T-DXd, both HER2-high & HER2-low pts achieved ORR>50%. Impressive activity for a rare, but very aggressive disease. High ILD rate (27%). https://t.co/TSgsbxhkha (@PTarantinoMD)

Thanks this is helpful. We are dealing with brain/spine ependymoma and metastatic spread to many parts of brain and spine, HER2 expression at 30% confirmed. (@CancerRevengers)

China’s Dr Binghe Xu discusses the unique differences of tumor characteristics of breast cancer among Asian patients vs US/European patients. ⬆️HER2 expression ⬆️TP53 mutations 🔥more active immune microenvironment #SGBCC2023 (@DrSGraff)

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 https://t.co/l6QlCVpqVN Is there hope for treatment tailoring in HER2 positive metastatic breast cancer? Congrats! Intriguing findings ()

It is good to know that T-DXd (Enhertu) met their target of overall response rate for HER2 expressing advanced solid tumors among 268 patients. Another step for proving the tremendous efficacy of HER2 targeting ADC. https://t.co/FULiKg9XJf (@teamoncology)

Press release from DESTINY-PanTumor02: T-DXd met the prespecified target for ORR & demonstrated durable responses across 268 patients with multiple HER2-expressing advanced solid tumours. 🔥Are we close to the first histology agnostic approval of an ADC? https://t.co/UhYu6K9OAe (@PTarantinoMD)

Interesting analysis results in #breastcancer with low ERBB2 level will be conjugated antibody-alpha by ERBB2, rather than biological features associated with low-level ERBB2 expression. https://t.co/G4FusgsBl0 (@Dr_Ivanoncologo)

As targeted agents for various levels of HER2 expression have demonstrated dynamic interoperability and efficacy, the prognosis for HER2-positive disease has improved. @BCJoyceO @DrDebuTripathy @maryam_lustberg #bcsm https://t.co/BPfkmIvKDJ (@OncLive)

As targeted agents for various levels of HER2 expression have demonstrated dynamic interoperability and efficacy, the prognosis for HER2-positive disease has improved. @BCJoyceO @DrDebuTripathy @maryam_lustberg #bcsm https://t.co/0zu1cPRL9n (@OncLive)

I agree, but I think HER2 expression in both TNBC/HR+ may be reflective of luminal biology. @ClintonYamMD presented work at SABCS that HER2-low TNBC were more likely AR+, as have other studies https://t.co/FHJ6ANyzzQ - so maybe enrichment for LAR drives these small differences (@fredhow)

The prognostic significance of HER2-low in TNBC becomes more evident in additional analysis according to the level of HER2 expression. HER2 IHC 2+ vs. HER2-zero HR➡️0.86-0.89 (approximately 12% relative risk reduction should warrant further investigation) (@dr_yakupergun)

I believe HER2 expression is important in TNBC, although not in HR-positive BC. There is a significant, albeit marginal, trend in favor of HER-low in stages 2, 3 and 4. I believe this difference will become clear when we separate HER2 0+ and 1+ more accurately. (@dr_yakupergun)

Glad to join @SchnittStuart & Jorge Reis-Filho for this @PeerView symposium. I expect a lot of interesting discussions on the evolving understanding of HER2 expression & its clinical significance in breast oncology. Join us in New Orleans or virtually! https://t.co/j3YxSRcwQi https://t.co/VvkVhGsHnQ (@PTarantinoMD)